Neurocrine Drug Patent Portfolio
Neurocrine owns 3 orange book drugs protected by 26 US patents Given below is the list of Neurocrine's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12128033 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | 09 Jun, 2041 | Active |
| US10940141 | Methods for the administration of certain VMAT2 inhibitors | 10 Aug, 2040 | Active |
| US11026931 | Methods for the administration of certain VMAT2 inhibitors | 14 Aug, 2039 | Active |
| US11654142 | Methods for the administration of certain VMAT2 inhibitors | 14 Nov, 2038 | Active |
| US11026939 | High dosage valbenazine formulation and compositions, methods, and kits related thereto | 18 Sep, 2038 | Active |
| US11311532 | High dosage valbenazine formulation and compositions, methods, and kits related thereto | 18 Sep, 2038 | Active |
| US10857137 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US10857148 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US10874648 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US10912771 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US10952997 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US10993941 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US11040029 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US11439629 | Methods for the administration of certain VMAT2 inhibitors | 10 Oct, 2037 | Active |
| US10906902 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | 22 Dec, 2036 | Active |
| US10906903 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | 22 Dec, 2036 | Active |
| US10919892 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) | 22 Dec, 2036 | Active |
| US10065952 | Valbenazine salts and polymorphs thereof | 28 Oct, 2036 | Active |
| US10844058 | Valbenazine salts and polymorphs thereof | 28 Oct, 2036 | Active |
| US10851103 | Valbenazine salts and polymorphs thereof | 28 Oct, 2036 | Active |
| US10851104 | Valbenazine salts and polymorphs thereof | 28 Oct, 2036 | Active |
| US10905690 | Treatment of congenital adrenal hyperplasia | 21 Jan, 2035 | Active |
| US11311544 | Treatment of congenital adrenal hyperplasia | 21 Jan, 2035 | Active |
| US11730739 | Treatment of congenital adrenal hyperplasia | 21 Jan, 2035 | Active |
| US8039627 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto | 11 Apr, 2031 | Active |
| US8357697 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto | 08 Nov, 2027 | Active |
Latest Legal Activities on Neurocrine's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Neurocrine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 12 Mar, 2025 | US8357697 |
| Post Issue Communication - Certificate of Correction | 12 Mar, 2025 | US8357697 |
| Initial letter Re: PTE Application to regulating agency | 10 Feb, 2025 | US11311544 |
| Initial letter Re: PTE Application to regulating agency | 10 Feb, 2025 | US11730739 |
| Initial letter Re: PTE Application to regulating agency | 10 Feb, 2025 | US10905690 |
| Patent Term Extension Application under 35 USC 156 Filed | 05 Feb, 2025 | US10905690 |
| Patent Term Extension Application under 35 USC 156 Filed | 05 Feb, 2025 | US11730739 |
| Patent Term Extension Application under 35 USC 156 Filed | 05 Feb, 2025 | US11311544 |
| Email Notification | 22 Jan, 2025 | US12128033 |
| Mail Patent eCofC Notification | 21 Jan, 2025 | US12128033 |
| Patent eCofC Notification | 21 Jan, 2025 | US12128033 |
| Recordation of Patent eCertificate of Correction | 21 Jan, 2025 | US12128033 |
| Mail Pub Notice re 312 amendment | 06 Jan, 2025 | US12128033 |
| Email Notification | 06 Jan, 2025 | US12128033 |
| Post Issue Communication - Certificate of Correction | 31 Dec, 2024 | US12128033 |
Neurocrine's Family Patents
Neurocrine drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 27.8% of its total global patent coverage. Click
below to unlock the full patent family tree.
Neurocrine Drug List
Given below is the complete list of Neurocrine's drugs and the patents protecting them.
1. Crenessity
Crenessity is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12128033 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine |
09 Jun, 2041
(15 years from now)
| Active |
| US10905690 | Treatment of congenital adrenal hyperplasia |
21 Jan, 2035
(8 years from now)
| Active |
| US11311544 | Treatment of congenital adrenal hyperplasia |
21 Jan, 2035
(8 years from now)
| Active |
| US11730739 | Treatment of congenital adrenal hyperplasia |
21 Jan, 2035
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crenessity's drug page
2. Ingrezza
Ingrezza is protected by 22 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10940141 | Methods for the administration of certain VMAT2 inhibitors |
10 Aug, 2040
(14 years from now)
| Active |
| US11026931 | Methods for the administration of certain VMAT2 inhibitors |
14 Aug, 2039
(13 years from now)
| Active |
| US11654142 | Methods for the administration of certain VMAT2 inhibitors |
14 Nov, 2038
(12 years from now)
| Active |
| US11026939 | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
18 Sep, 2038
(12 years from now)
| Active |
| US11311532 | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
18 Sep, 2038
(12 years from now)
| Active |
| US10857137 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10857148 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10874648 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10912771 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10952997 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10993941 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US11040029 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US11439629 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10906902 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
22 Dec, 2036
(10 years from now)
| Active |
| US10906903 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
22 Dec, 2036
(10 years from now)
| Active |
| US10919892 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
22 Dec, 2036
(10 years from now)
| Active |
| US10065952 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US10844058 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US10851103 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US10851104 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US8039627 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
11 Apr, 2031
(5 years from now)
| Active |
| US8357697 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
08 Nov, 2027
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ingrezza's drug page
3. Ingrezza Sprinkle
Ingrezza Sprinkle is protected by 22 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10940141 | Methods for the administration of certain VMAT2 inhibitors |
10 Aug, 2040
(14 years from now)
| Active |
| US11026931 | Methods for the administration of certain VMAT2 inhibitors |
14 Aug, 2039
(13 years from now)
| Active |
| US11654142 | Methods for the administration of certain VMAT2 inhibitors |
14 Nov, 2038
(12 years from now)
| Active |
| US11026939 | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
18 Sep, 2038
(12 years from now)
| Active |
| US11311532 | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
18 Sep, 2038
(12 years from now)
| Active |
| US10857137 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10857148 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10874648 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10912771 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10952997 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10993941 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US11040029 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US11439629 | Methods for the administration of certain VMAT2 inhibitors |
10 Oct, 2037
(11 years from now)
| Active |
| US10906902 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
22 Dec, 2036
(10 years from now)
| Active |
| US10906903 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
22 Dec, 2036
(10 years from now)
| Active |
| US10919892 | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
22 Dec, 2036
(10 years from now)
| Active |
| US10065952 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US10844058 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US10851103 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US10851104 | Valbenazine salts and polymorphs thereof |
28 Oct, 2036
(10 years from now)
| Active |
| US8039627 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
11 Apr, 2031
(5 years from now)
| Active |
| US8357697 | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
08 Nov, 2027
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ingrezza Sprinkle's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List